Gut Podcast cover art

All Episodes

Gut Podcast — 129 episodes

#
Title
1

Eosinophilic oesophagitis: the therapeutic potential of FOXM1 inhibition

2

Long-term prognosis of lean MASLD: evidence from three population-based prospective cohorts

3

Managing type 2 diabetes patients with MASLD

4

Targeting MASLD with new nanoparticles

5

Performance of the China-CLIF framework in acute-on-chronic liver failure

6

Predicting short-term liver transplant outcomes with graft microbial DNA signature

7

Screening and eradication of H pylori for gastric cancer prevention: Taipei Global Consensus II

8

Helicobacter pylori antibiotic resistance: a global challenge in search of solutions

9

Effective treatment of severe acute pancreatitis using COX-2 inhibitors

10

Protecting against Crohn's disease with dietary whey protein

11

Comparing diclofenac and indomethacin for prevention of post-ERCP pancreatitis

12

Studying oat ingestion in coeliac disease with purified oat protein

13

Predicting sensitivity to dietary emulsifiers using an in-vitro microbiota model

14

Antiviral treatment of chronic Hepatitis B

15

Single-cell spatial profiling of immunotypes in hepatocellular carcinoma

16

Understanding the gut-adipose-liver axis and its impact on insulin action

17

Linking breastfeeding and atopic dermatitis in infants

18

Improving CLDN18.2 BiTEs efficacy against pancreatic cancer

19

Gut microbiota signatures of vulnerability to food addiction in mice and humans

20

Gastric intestinal metaplasia: reviewing current guidelines

21

Exploring stem cell therapy for Hirschsprung disease

22

Protective function of sclerosing cholangitis on IBD

23

Linking high-fat diet and liver tumorigenesis

24

Hepatocellular carcinoma in patients with liver cirrhosis

25

Microbiome interventions for COPD protection

26

MASLD: a systemic metabolic disorder with cardiovascular and malignant complications

27

RE.GA.IN: the Real-world Gastritis Initiative

28

Prebiotic diet changes neural correlates of food decision-making in overweight adults

29

Lethal sepsis prevention with novel tripeptide RKH derived from Akkermansia muciniphila

30

Special Gut Podcast: Digestive health and climate change

31

Gastrointestinal origins for Parkinson’s disease

32

Consensus definition of sludge and microlithiasis as a possible cause of pancreatitis

33

Rome consensus on gut microbiota and faecal microbiota transplantation in IBD

34

The therapeutic potential of fasting

35

Helicobacter pylori promotes colorectal carcinogenesis

36

Single-cell transcriptomics sheds new light on pancreas biology and disease

37

Counteracting the harm of dietary emulsifiers with Akkermansia muciniphila

38

Antibiotic use as a risk factor for IBD

39

Predicting disease progression in bridging fibrosis and cirrhosis with liver stiffness

40

Assessing the impact of dietary fibre on bile acid transformation by gut bacteria in mice

41

Autoimmune gastritis: cancer risk in consistently tested H. pylori-negative patients

42

FMT-AID trial shows effectiveness in inducing remission of ulcerative colitis

43

Endoscopic pyloromyotomy for the treatment of severe and refractory gastroparesis

44

Climate change: a survey of global gastroenterology society leadership

45

Management of Helicobacter pylori infection — the Maastricht VI/Florence Consensus Report

46

Kyoto international consensus report on the gastro-oesophageal junction

47

A faecal microbiota signature with high specificity for pancreatic cancer

48

PICaSSO Histologic Remission Index in ulcerative colitis: a novel simplified histological score

49

Next-generation sequencing of bile cell-free DNA for early detection of malignant biliary strictures

50

Endoscopic full-thickness plication for the treatment of PPI-dependent GERD

51

Dysosmobacter welbionis, a new human commensal bacterium preventing diet-induced obesity

52

Gut microbiota modulates COPD pathogenesis: role of anti-inflammatory Pg-LPS

53

Proton pump inhibitors and risk of colorectal cancer

54

Sugar-sweetened beverage intake and risk of early-onset colorectal cancer among women

55

Diet quality and risk and severity of COVID-19: a prospective cohort study

56

Helicobacter pylori resistance to antibiotics in Europe

57

Blue poo: impact of gut transit time on the gut microbiome using a novel marker

58

Long-term dietary patterns associated with inflammatory features of the gut microbiome

59

Association between Brachyspira and irritable bowel syndrome with diarrhoea

60

Effect of IBD medications on COVID-19 outcomes

61

CLARITY IBD: Anti-SARS-CoV-2 antibody and vaccination responses in patients treated with infliximab

62

Long-term instability of the intestinal microbiome and its associations

63

Neutrophils interact with cholangiocytes to cause cholestatic changes in alcoholic hepatitis

64

Screening and eradication of Helicobacter pylori for gastric cancer prevention

65

European Registry on Helicobacter pylori management (Hp-EuReg)

66

Driving the efficacy of prebiotic intervention in obese patients

67

Adipose tissue derived bacteria are associated with inflammation in obesity and type 2 diabetes

68

Global burden of oesophageal and gastric cancer by histology and subsite in 2018

69

Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease

70

Efficacy of FMT for patients with IBS in a randomised, double-blind, placebo-controlled study

71

Infants born to mothers with IBD present with altered gut microbiome

72

Mediterranean diet intervention alters the gut microbiome in older people

73

Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus

74

British Society of Gastroenterology guidance for management of IBD during the Covid-19 pandemic

75

Global patterns and trends in colorectal cancer incidence in young adults

76

Guidelines on the management of inflammatory bowel disease in adults

77

European evidence-based guidelines on pancreatic cystic neoplasms

78

Viral transfer during FMT linked to better outcomes in recurrent C. diff bacterial infections

79

Colorectal cancer: research prioritisation needed in third most lethal malignancy worldwide

80

Development of an FGF19-based chimeric molecule to promote fatty liver regeneration

81

Feeding the microbiota: transducer of nutrient signals for the host

82

Dietary emulsifiers directly alter human microbiota composition

83

Faecal microbiota transplantation in clinical practice

84

BMP-9 interferes with liver regeneration and promotes liver fibrosis

85

A systematic review of isolated colonic Crohn’s disease: the third IBD?

86

Gut microbiome and liver diseases

87

Antibiotics as deep modulators of gut microbiota: between good and evil.

88

Asia-Pacific consensus on the management of gastro-oesophageal reflux disease

89

Surveillance endoscopy is associated with improved outcomes of oesophageal adenocarcinoma

90

Live birth and adverse birth outcomes in women with ulcerative colitis and Crohn’s disease

91

GLP-1 based therapies: clinical implications for gastroenterologists

92

Dysbiotic gut microbiota causes transmissible Crohn’s disease-like ileitis

93

Mesalazine and thymoquinone attenuate intestinal tumour development in mice

94

Effects of bowel cleansing on the intestinal microbiota

95

Development of an enhanced human gastrointestinal epithelial culture system

96

Helicobacter pylori targets cancer-associated apical-junctional constituents

97

Diagnosis and management of acute kidney injury in patients with cirrhosis

98

Demonstration of the usefulness of epigenetic cancer risk prediction

99

XIAP variants in male Crohn’s disease

100

Cell lineage distribution atlas reveals heterogeneous gland populations in the gastric antrum

101

Classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn’s disease

102

Update on basic and clinical aspects of eosinophilic oesophagitis

103

AIEC pathobiont instigates chronic colitis in susceptible hosts by altering microbiota composition

104

Besifovir versus entecavir in Asian patients with chronic hepatitis B

105

Characterisation of faecal protease activity in irritable bowel syndrome with diarrhoea

106

Recent advances in clinical practice challenges and opportunities in the management of obesity

107

Amniotic stem cell treament for necrotic enterocolitis

108

British Society of Gastroenterology guidelines on diagnosing and managing Barrett’s oesophagus

109

Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients

110

A systematic approach to therapeutic target selection in oesophago-gastric cancer

111

Gut podcast: Treatment of pancreatic fibrosis with siRNA

112

Intra-tumoural stroma as a predictor of survival in patients with gastric cancer

113

Probiotics in health and disease

114

Transcriptional analysis of the intestinal mucosa of patients with ulcerative colitis in remission

115

mTNF reverse signalling induced by TNFα antagonists involves a GDF-1 dependent pathway

116

Endoscopic improvement of mucosal lesions in patients with ileocolonic Crohn’s disease

117

Bowel cancer screening in England

118

PUFAS and neoplasms

119

Cancer treatment induced gastrointestinal symptoms

120

Bifidobacterium and gastrointestinal inflammation

121

High-fat diet and gut microbiota

122

Management of Helicobacter pylori infection

123

Assessment of colorectal cancer molecular features

124

Probiotic and postbiotic activity in health and disease

125

NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease

126

Outcomes of the Bowel Cancer Screening Programme in England

127

Mucosal healing in inflammatory bowel disease

128

Interleukin 13 and its role in gut defence and inflammation

129

Revising the classification of acute pancreatitis